A Multicenter, Single Arm Phase II Clinical Study Evaluating the Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Seasonal Allergic Rhinitis
Latest Information Update: 11 Nov 2024
Price :
$35 *
At a glance
- Drugs Stapokibart (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
- Sponsors KeyMed Biosciences
- 21 Jun 2023 New trial record